ArticleThe Biochemical journal2011
A functional family-wide screening of SP/KLF proteins identifies a subset of suppressors of KRAS-mediated cell growth.
Article in The Biochemical journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer.Nature genetics · 2014Pooled it
- A Novel Emerin/Nesprin-3 Interaction Mediates Nuclear Size Changes Induced by Oncogenic KRAS in Pancreatic Cancer Cells.Molecular and cellular biology · 2026Article
- Chromatin Remodeling in Patient-Derived Colorectal Cancer Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Molecular Mechanisms of IL18 in Disease.International journal of molecular sciences · 2023Review
- Review
- Kruppel-like factor 13 acts as a tumor suppressor in thyroid carcinoma by downregulating IFIT1.Biology direct · 2023Article
- Downregulation of Krüppel-like factor 14 accelerated cellular senescence and aging.Aging cell · 2023Article
- The lncRNA Tincr Regulates the Abnormal Differentiation of Intestinal Epithelial Stem Cells in the Diabetic StateCurrent stem cell research & therapy · 2023Article
- Determining KLF14 tertiary structure and diagnostic significance in brain cancer progression.Scientific reports · 2022Article
- Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice.PLoS pathogens · 2022Article
- Kruppel like factor 16 promotes lung adenocarcinoma progression by upregulating lamin B2.Bioengineered · 2022Article
- Expression and Prognosis Value of the KLF Family Members in Colorectal Cancer.Journal of oncology · 2022Article
- Parallel characterization of cis-regulatory elements for multiple genes using CRISPRpath.Science advances · 2021Article
- EZH2-mediated inhibition of KLF14 expression promotes HSCs activation and liver fibrosis by downregulating PPARγ.Cell proliferation · 2021Article
- Discover novel disease-associated genes based on regulatory networks of long-range chromatin interactions.Methods (San Diego, Calif.) · 2021Article
- Article
- Comparative Enhancer Map of Cattle Muscle Genome Annotated by ATAC-Seq.Frontiers in veterinary science · 2021Article
- Predictive Biomarkers of Dicycloplatin Resistance or Susceptibility in Prostate Cancer.Frontiers in genetics · 2021Article
- A novel mechanism driving poor-prognostic gastric cancer: overexpression of the transcription factor Krüppel-like factor 16 promotes growth and metastasis of gastric cancer through regulating the Notch pathway.American journal of cancer research · 2021Article
- Clinical and Functional Characteristics of a NovelJournal of diabetes research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
SP/KLF (Specificity protein/Krüppel-like factor) transcription factors comprise an emerging group of proteins that may behave as tumour suppressors. Incidentally, many cancers that display alterations in certain KLF proteins are also associated with a high incidence of KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue) mutations. Therefore in the present paper we investigate whether SP/KLF proteins suppress KRAS-mediated cell growth, and more importantly, the potential mechanisms underlying these effects. Using a comprehensive family-wide screening of the 24 SP/KLF members, we discovered that SP5, SP8, KLF2, KLF3, KLF4, KLF11, KLF13, KLF14, KLF15 and KLF16 inhibit cellular growth and suppress transformation mediated by oncogenic KRAS. Each protein in this subset of SP/KLF members individually inhibits BrdU (5-bromo-2-deoxyuridine) incorporation in KRAS oncogenic-mutant cancer cells. SP5, KLF3, KLF11, KLF13, KLF14 and KLF16 also increase apoptosis in these cells. Using KLF11 as a representative model for mechanistic studies, we demonstrate that this protein inhibits the ability of cancer cells to form both colonies in soft agar and tumour growth in vivo. Molecular studies demonstrate that these effects of KLF11 are mediated, at least in part, through silencing cyclin A via binding to its promoter and leading to cell-cycle arrest in S-phase. Interestingly, similar to KLF11, KLF14 and KLF16 mechanistically share the ability to modulate the expression of cyclin A. Collectively, the present study stringently defines a distinct subset of SP/KLF proteins that impairs KRAS-mediated cell growth, and that mechanistically some members of this subset accomplish this, at least in part, through regulation of the cyclin A promoter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.